Auris Medical Holding AG (NASDAQ:EARS) saw an uptick in trading volume on Tuesday . 160,492 shares were traded during mid-day trading, an increase of 4% from the previous session’s volume of 154,259 shares.The stock last traded at $3.87 and had previously closed at $3.79.

A number of research firms have recently weighed in on EARS. Zacks Investment Research raised shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Tuesday, July 12th. Jefferies Group reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $12.00 target price on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th.

The stock’s market cap is $71.23 million. The company’s 50 day moving average is $4.09 and its 200 day moving average is $3.96.

Auris Medical Holding AG (NASDAQ:EARS) last posted its quarterly earnings data on Thursday, August 18th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.01. On average, analysts predict that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.